News | EP Mapping and Imaging Systems | May 04, 2016

Acutus Medical Receives CE Mark for AcQMap 3-D Imaging and Mapping System

Company to initiate commercial activities for next-generation imaging and mapping system

Acutus Medical, AcQMap EP Imaging and Mapping System, CE Mark

May 4, 2016 — Acutus Medical announced CE Mark approval for its AcQMap High Resolution Imaging and Mapping System and AcQMap Catheter, enabling the company to initiate commercial activities.

According to the company, the system is the first and only to detect and display both standard voltage-based and higher resolution charge-source (dipole density) maps. The system is also able to generate real-time, 3-D images of the heart chamber using ultrasound with quality comparable to a computed tomography (CT) or magnetic resonance imaging (MRI) in a matter of minutes. Dipole, non-contact mapping creates a highly accurate, instantaneous global view that captures the activation pattern of every heartbeat making it uniquely capable of mapping and displaying both stable and unstable cardiac arrhythmias.

“During a recent AcQMap procedure, we were able to systematically map atrial fibrillation (AF) and eliminate the identified sites of interest, ultimately restoring the patient to their native rhythm,” said Andrew Grace, M.D., Ph.D., from Cambridgeshire, U.K.-based Papworth Hospital. “The ability to map and quickly re-map after each set of ablations makes it possible to truly visualize AF and to achieve sinus rhythm.”

The AcQMap High Resolution Imaging and Mapping System is not available for sale in the United States.

For more information: www.acutusmedical.com


Additional Content

Feature | EP Lab | Lars Thording, PhD

Medical device portfolios now move on two very different clocks. New technologies can gain clinical adoption within ...

Home October 14, 2026
Home
News | EP Lab

July 7, 2026 —AtaCor Medical has announced the enrollment of the first patient in the company's ALARION-EV trial ...

Home July 09, 2026
Home
News | EP Lab

April 17, 2026 — Corify Care has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for ...

Home April 20, 2026
Home
News | EP Lab

Jan. 28, 2026 — Corify Care has announced a major development in cardiac electrophysiology with the publication of its ...

Home January 29, 2026
Home
News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
Subscribe Now